| Primary |
| Crohn's Disease |
40.0% |
| Colitis Ulcerative |
20.0% |
| Anal Fissure |
6.7% |
| Gastrointestinal Inflammation |
6.7% |
| Proctitis |
6.7% |
| Proctitis Ulcerative |
6.7% |
| Product Used For Unknown Indication |
6.7% |
| Ulcerative Proctitis |
6.7% |
|
| Weight Decreased |
21.4% |
| Pancreatitis Acute |
14.3% |
| Arthritis |
7.1% |
| Headache |
7.1% |
| Hospitalisation |
7.1% |
| Meniscus Injury |
7.1% |
| Pancreatitis |
7.1% |
| Rectal Haemorrhage |
7.1% |
| Thrombocytopenia |
7.1% |
| Thrombosis |
7.1% |
| Urticaria |
7.1% |
|
| Secondary |
| Crohn's Disease |
46.7% |
| Colitis |
20.0% |
| Colitis Ulcerative |
20.0% |
| Acne |
6.7% |
| Anorectal Disorder |
6.7% |
|
| Weight Decreased |
25.0% |
| Blister |
12.5% |
| Drug Ineffective |
12.5% |
| Gait Disturbance |
12.5% |
| Pericarditis |
12.5% |
| Suicidal Ideation |
12.5% |
| Unevaluable Event |
12.5% |
|
| Concomitant |
| Crohn's Disease |
27.3% |
| Product Used For Unknown Indication |
21.8% |
| Colitis Ulcerative |
15.6% |
| Drug Use For Unknown Indication |
13.2% |
| Colitis |
3.9% |
| Hypertension |
2.5% |
| Pain |
2.4% |
| Gastrooesophageal Reflux Disease |
1.8% |
| Depression |
1.7% |
| Vitamin Supplementation |
1.5% |
| Anxiety |
1.3% |
| Blood Cholesterol Increased |
0.9% |
| Premedication |
0.9% |
| Blood Pressure |
0.8% |
| Diarrhoea |
0.8% |
| Contraception |
0.7% |
| Supplementation Therapy |
0.7% |
| Hypersensitivity |
0.7% |
| Hypothyroidism |
0.7% |
| Mineral Supplementation |
0.7% |
|
| Weight Decreased |
16.8% |
| Colitis Ulcerative |
8.8% |
| Injection Site Pain |
8.8% |
| Pyrexia |
7.2% |
| Vomiting |
7.2% |
| Weight Increased |
5.6% |
| Urinary Tract Infection |
4.8% |
| Dyspnoea |
4.0% |
| Pain |
4.0% |
| Therapeutic Response Decreased |
4.0% |
| Fatigue |
3.2% |
| Haematochezia |
3.2% |
| Infection |
3.2% |
| Influenza |
3.2% |
| Sinusitis |
3.2% |
| Viral Infection |
3.2% |
| Abdominal Pain |
2.4% |
| Abdominal Pain Upper |
2.4% |
| Cough |
2.4% |
| Dehydration |
2.4% |
|
| Interacting |
| Hypertension |
66.7% |
| Arthritis |
33.3% |
|
|
